新活素联合左卡尼丁治疗顽固性心力衰竭临床研究

目的 观察新活素联合左卡尼丁治疗顽固性心力衰竭临床疗效.方法 2016年2月至2017年2月顽固性心力衰竭患者204例,随机分为对照组（新活素治疗）及观察组（新活素联合左卡尼丁治疗）各102例,比较两组临床疗效.结果 治疗前两组心功能、血浆N末端脑钠肽前体、6MWT差异无统计学意义.治疗后观察组各项指标数值明显优于对照组,差异有统计学意义（P〈0.05）.观察组不良反应发生率3.92％,对照组不良反应发生率2.94％,两组比较差异无统计学意义（P〉0.05）.结论 在顽固性心力衰竭的临床治疗工作中新活素联合左卡尼丁取得的疗效更佳,可作为优选治疗方案推广使用.

Objective To observe the clinical efficacy of combination oflyophilized recombinant human brain natriuretic peptide and levocamitine in treatment of refractory heart failure. Methods Totally 204 patients with refractory heart faiklre from February 2016 to Febmary 2017 were randomly divided into two groups ： control group （ lyophilized recombinant human brain natriuretic peptide treatment ） and observation group （ lyophilized recombinant human brain natriuretic peptide combined with levocamitine treatment ） , the clinical efficacy was compared between the two groups. Results Before treatment, there was no significant difference in cardiac function, plasma N-terminal pro brain natriuretic peptide and 6MWT. After treatment, the indexes in the observation group were significantly better than those in the control group, the difference was statistically significant （ P〈0.05 ） . The incidence of adw＇rse reactions in the observation group was 3.92%, while the incidence of adverse reactions in the control group was 2.94%. There was no significant difference between the two groups （ P〉0.05 ） . Conclusion In the clinical treatment of intractable heart failnre, lyophilized recombinant human brain uatriuretic peptide combined with levocamitine has better curative effect and can be used as the preferred treatment plan.